On Wednesday, H.C. Wainwright reaffirmed a Buy rating and a price target of $54.00 on Biohaven Pharmaceutical (TADAWUL:2070) ...

This guide covers all the logo design rules, best practices, tips, examples, and more to equip you with the knowledge for crafting brilliant logos. Logos are one of the most vital elements of any ...

This is reflected in the fact that the Association of the British Pharmaceutical Industry (ABPI) and the European Federation of Pharmaceutical Industries and Associations (EFPIA) have also ...

H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Biohaven Pharmaceutical Holding Co (NYSE:BHVN) Ltd on Tuesday,... H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on ...

HC Wainwright reissued their buy rating on shares of Biohaven (NYSE:BHVN – Free Report) in a report issued on Tuesday,Benzinga reports. The firm currently has a $54.00 price target on the stock.

NEW YORK, NY / ACCESS Newswire / March 4, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biohaven Ltd. ("Biohaven Ltd.") (NYSE:BHVN) concerning possible ...

In a report released yesterday, Leonid Timashev from RBC Capital maintained a Buy rating on Biohaven Ltd. (BHVN – Research Report), with a price target of $61.00. The company’s shares closed ...

Today, a brief rundown of news involving Acelyrin and Neumora Therapeutics, as well as updates from Biohaven, Lexicon Pharmaceuticals and Pliant Therapeutics you may have missed. Shares of Lexicon ...

Biohaven acquired BHV-7000 as part of a February 2022 buyout of Channel Biosciences. Image credit: Shutterstock / ma_Design. Biohaven’s pipeline drug BHV-7000 has failed to meet the primary endpoint ...

Open innovation in medical and pharmaceutical research has grown steadily over the last decade. However, the performance of the published literature in terms of the scientific impact and gaining ...

Biohaven’s bipolar disorder candidate has failed to improve mania symptoms in a phase 2/3 trial. The registrational study assessed BHV-7000, a drug designed to selectively activate Kv7.2/Kv7.3 ...